Hydroxyurea is a nucleoside diphosphate reductase inhibitor that prevents the reduction of nucleotides to deoxynucleotides, interferes with the biosynthesis of purine and pyrimidine bases, and selectively hinders DNA synthesis. Research data for the treatment of sickle cell anemia shows that compared with pre-treatment levels, the use of hydroxyurea and SCA patients reduce pain by an average of 55%, infections by 38%, malaria by 51%, blood transfusions by 67%, and mortality by 70%. related.

Another study has explored the application of a pharmaceutical composition containing hydroxyurea in the preparation of drugs for the prevention and/or treatment of atherosclerosis. A combination of pidogrel or atorvastatin calcium alone).

Hydroxyurea has a long history of clinical application in antiviral and antitumor aspects, and it is still the first-line drug for many diseases. In recent years, with the continuous expansion of the scope of clinical application, many new clinical uses of hydroxyurea have gradually been discovered. Sickle cell anemia, β-thalassemia, psoriasis, polycythemia vera, essential thrombocythemia, and AIDS have all achieved good results.

At present, hydroxyurea is listed as China's domestic medical insurance category A, and it is the first-line medicine for various diseases. The supply of domestic raw materials is in short supply. Our company can supply high-quality imported raw materials. Joint declaration is supported. Consultation and cooperation are welcome.